(two upper panels) and KOPN8 (two lower panels), exposed for 6, 24 and 48 hours to either vehicle (DMSO) or Selumetinib, MEK162 or Trametinib, detecting phosphorylated ELK-1 and total ELK-1. B. Western blots of SEM and KOPN8, exposed to aforementioned MEK inhibitor conditions, for phosphorylated and total Akt. C. Western blots of SEM and KOPN8, exposed to aforementioned MEK inhibitor conditions, for phosphorylated and total p70S6K.
Supplementary Figure 6: Cell cycle progression after MEK inhibitor exposure. Representative graphs of percentages SEM
A, C and E. or KOPN8 B, D and F. cells in G2/M (white), S (grey) or G0/G1 (black) cell cycle stages, as analyzed by DNA staining. Cells were exposed to vehicle control (DMSO) or 500 nM MEK162, Selumetinib or Trametinib for 24, 48 or 72 hours (A and B, C and D, E and F, respectively).
